Evidence map›Paper›PMID 41142139›Full record

ArticleJTO clinical and research reports2025

A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC.

Kensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, Akihiro Tsukaguchi, Nao Shoshihara, Koki Moritomo, Yuhei Kinehara, Yasuhiro Mihashi, Tomoki Kuge, Midori Yoneda and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Kensuke KanaokaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Kinnosuke MatsumotoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Takayuki ShiroyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Akihiro TsukaguchiDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Nao ShoshiharaDepartment of Respiratory Medicine, Osaka Keisatsu Hospital, Osaka, Japan.
Koki MoritomoDepartment of Respiratory Medicine, Osaka Keisatsu Hospital, Osaka, Japan.
Yuhei KineharaDepartment of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital, Osaka, Japan.
Yasuhiro MihashiDepartment of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Tomoki KugeDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Midori YonedaDepartment of Respiratory Medicine, Ikeda Municipal Hospital, Osaka, Japan.
Soichiro KatoDepartment of Respiratory Medicine, Ikeda Municipal Hospital, Osaka, Japan.
Keijiro YamauchiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hirotomo MachiyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Yuki NishikawaDepartment of Respiratory Medicine, Toyonaka Municipal Hospital, Osaka, Japan.
Osamu MorimuraDepartment of Respiratory Medicine, Toyonaka Municipal Hospital, Osaka, Japan.
Akito MiyazakiDepartment of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
Kiyohide KomutaDepartment of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
Kouji AzumaDepartment of Respiratory Medicine, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Satoshi TanakaLocal Independent Administrative Agency Osaka Prefectural Hospital Organization Osaka General Medical Center, Osaka, Japan.
Toshie NikiDepartment of Respiratory Medicine, Nishinomiya Municipal Central Hospital, Hyogo, Japan.
Akio OsaDepartment of Respiratory Medicine, Kinki Central Hospital, Hyogo, Japan.
Akihiro TamiyaDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Motohiro TamiyaDepartment of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
Hidekazu SuzukiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Masahide MoriDepartment of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Yoshito TakedaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Evidence of immune checkpoint inhibitors (ICIs) combined with chemotherapy for older patients with NSCLC is limited. This real-world study compared the efficacy and safety of atezolizumab plus chemotherapy (ACT) with those of pembrolizumab plus chemotherapy (PCT) for older patients with advanced nonsquamous NSCLC. Methods: This multicenter, retrospective study included 288 patients 65 years or older with advanced or recurrent nonsquamous NSCLC who received PCT or ACT as first-line treatment at 13 institutions in Japan. After one-to-one propensity score matching, overall survival (OS), the incidence of grade 3 or higher treatment-related adverse events, and all-grade pneumonitis of the PCT and ACT groups were compared. Results: After propensity score matching, 54 patients were included in each of the groups. OS did not significantly differ between the PCT and ACT groups. The median OS was 16.6 months for both groups. Compared with the PCT group, the ACT group had a hazard ratio of 1.09 (95% confidence interval [CI]: 0.68-1.74; Conclusions: ACT may be associated with a more favorable safety profile than that of PCT for the Japanese population; therefore, ACT could be considered a treatment option for older patients with advanced nonsquamous NSCLC.

Indexed as

AtezolizumabImmune checkpoint inhibitorsImmune-related adverse eventsNon–small cell lung cancerPembrolizumabPneumonitis

Identifiers

PMID41142139
PMCPMC12547812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.